Xoma News (NASDAQ:XOMA)

DateTimeSource
Headline
04/24/20177:00AMGLOBEXOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition
BERKELEY, Calif., April 24, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced that it has achieved positive Phase 2 proof-of-concept results for X213 in physiological hyperprolactinemia (HPRL). X213 is a monoclonal antibody that... More...>>
04/18/20177:00AMGLOBEXOMA Presents Positive Data from PTH1R Monoclonal Antibody Program
BERKELEY, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today the presentation of positive data from pre-clinical studies investigating the activity of its anti-PTH1R antagonist monoclonal antibody (mAb). The antibody... More...>>
03/28/20177:00AMGLOBEXOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research...
BERKELEY, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today the presentation of data from its PTH1R Monoclonal Antibodies Program. The poster, which reports data from a pre-clinical study investigating the efficacy... More...>>
03/23/20177:00AMGLOBEXOMA Announces Four Presentations at the 2017 ENDO Meeting
BERKELEY, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today that clinical data for its two hypoglycemia drug candidates, X358 and X129, and a third drug candidate for hypercalcemic endocrine and oncology conditions... More...>>
03/22/20177:00AMGLOBEXOMA Announces Full Repayment of Hercules Technology Growth Capital Debt Obligation
BERKELEY, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today it has fully prepaid the outstanding balance of approximately $6.5 million under the Company’s term loan with Hercules Technology Growth Capital, Inc... More...>>
03/16/20177:00AMGLOBEXOMA Reports Fourth Quarter and Full Year 2016 Financial Results
Actions taken in 2016 set the stage for reduced operating costs and capital requirements In early 2017, Company established new strategic direction and value drivers BERKELEY, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies... More...>>
03/14/20177:00AMGLOBEXOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call Focused on its New Strategic Di...
BERKELEY, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today it will issue its fourth quarter and full year 2016 financial results before the market opens on Thursday, March 16, 2017. In conjunction, the Company... More...>>
02/28/20177:00AMGLOBEXOMA to Present New Strategic Initiatives at the Cowen and Company 37th Annual Health Care Conference
BERKELEY, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Jim Neal, Chief Executive Officer, will present the company’s new strategic initiatives and value drivers at the Cowen and Company 37th Annual Health... More...>>
02/16/20177:00AMGLOBEXOMA Appoints Matthew Perry to its Board of Directors
BERKELEY, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Matthew Perry, President of BVF Partners L.P. (BVF), to the XOMA Board of Directors. “On behalf of the entire XOMA team, we are thrilled... More...>>
02/13/20177:00AMGLOBEXOMA Announces Pricing of $25 Million Registered Offering of Common Stock and Convertible Preferred Stock
BERKELEY, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) announced today that it has agreed to sell 1,200,000 shares of its common stock and 5,003 shares of convertible preferred stock directly to Biotechnology Value Fund, L.P. and certain of its affiliates (“BVF”) in a registered direct offering. ... More...>>
01/31/20174:00PMGLOBEXOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery
BERKELEY, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that it has established proof-of-concept for its product candidate 358 in congenital hyperinsulinism (CHI) and hypoglycemia post-bariatric surgery (PBS... More...>>
12/30/201610:30AMBWJanuary 6 Deadline Alert: Law Offices of Howard G. Smith Reminds Exxon Mobil Corp. Investors of Upcoming Lead Plaintiff Deadl...
Investors with $500,000 or more in losses are encouraged to contact the Firm. Law Offices of Howard G. Smith reminds investors of the upcoming January 6, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Exxon Mobil Corporation (“Exxon” or the “Company”... More...>>
12/29/201610:30AMBWGPM Reminds Investors of the January 6th Deadline in the Class Action Lawsuit Against Exxon Mobil Corp. & Encourages Investor...
Investors with losses over $1,000,000 are encouraged to contact the Firm. Glancy Prongay & Murray LLP (“GPM”) reminds investors of the January 6, 2017 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired Exxon Mobil Corporation (“Exxon”... More...>>
12/23/201612:52PMBWThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Exxon Mobil Corp. Investors...
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Exxon Mobil Corporation (“Exxon” or the “Company”) (NASDAQ: XOM) securities between February 19, 2016 and October 27, 2016, inclusive (the “Class Period”). Exxon investors have until January... More...>>
12/21/20165:00PMGLOBEXOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Pa...
Up to $22 million in revenue generated through sale of royalty streams from two license agreements to HealthCare Royalty Partners, with an initial $18 million payment and up to $4 million in future milestonesNon-dilutive funding to support clinical advancement of XOMA 358 in a streamlined mannerOperational transformation... More...>>
11/23/20161:57PMBWINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Exxon Mobile Corporation Investors
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Exxon Mobile Corporation (“Exxon” or the “Company”) (NASDAQ: XOM) concerning the Company and its officers’ possible violations of federal securities laws. On October 28, 2016, Exxon announced that the Company could potentially... More...>>
11/15/20162:53PMBWGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Exxon Mobil Corp. Investors & Encourag...
Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Exxon Mobil Corporation (“Exxon” or the “Company”) (NASDAQ: XOM) securities between February 19, 2016 and October 27, 2016, inclusive (the “Class Period”). Exxon investors have... More...>>
11/09/20169:00AMGLOBEXOMA Reports Third Quarter 2016 Achievements and Financial Results
BERKELEY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and financial results for the third quarter ended September 30, 2016. “In the third quarter, we accelerated activity in our XOMA... More...>>
11/08/20169:00AMGLOBENew XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual Meeting
Preclinical Data from XOMA’s Novel Anti-IL-2 Immuno-oncology Monoclonal Antibodies Program to be Presented at SITCAdvancing Unique Functional Antibody Antagonists Targeting the Parathyroid Hormone Receptor 1 (PTH1R)Plan to Out-license IL-2 and PTH1R Programs to Fund Endocrine Efforts BERKELEY, Calif., Nov. 08, 2016 (GLOBE... More...>>
10/19/20169:00AMGLOBEXOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital H...
BERKELEY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted in principle the Company’s proposal to initiate a multi-dose... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:us D:20170430 08:51:01